Skip to main content

Breadcrumb

  1. Home

Pharmacy Quality Alliance

Antipsychotic Use in Persons with Dementia

  • The percentage of individuals 65 years and older with dementia who are receiving an antipsychotic medication without evidence of a psychotic disorder or related condition.

    A lower rate indicates better performance.

    CBE ID
    2111

Concurrent Use of Opioids and Benzodiazepines (COB)

  • The percentage of individuals >=18 years of age with concurrent use of prescription opioids and benzodiazepines during the measurement year.

    A lower rate indicates better performance.

    CBE ID
    3389

Diabetes: Appropriate Treatment of Hypertension

  • The percentage of patients who were dispensed a medication for diabetes and hypertension that are receiving an angiotensin-converting -enzyme-inhibitor (ACEI) or angiotensin receptor blocker (ARB) or direct renin inhibitor (DRI) renin-angiotensin-antagonist medication.

    CBE ID
    0546

INR Monitoring for Individuals on Warfarin

  • Percentage of individuals at least 18 years of age as of the end of the measurement period with at least 56 days of warfarin therapy who receive at least one International Normalized Ratio (INR) test during each 56-day interval with active warfarin therapy.

    CBE ID
    0555

Proportion of Days Covered (PDC): 3 Rates by Therapeutic Category

  • The percentage of individuals 18 years and older who met the Proportion of Days Covered (PDC) threshold of 80 percent during the measurement year.

    Report a rate for each of the following:
    • Diabetes All Class (PDC-DR)
    • Renin Angiotensin System Antagonists (PDC-RASA)
    • Statins (PDC-STA)

    A higher rate indicates better performance.

    CBE ID
    0541

Statin Use in Persons with Diabetes

  • The percentage of patients ages 40 to 75 years who were dispensed a medication for diabetes that receive a statin medication.

    CBE ID
    2712

Suboptimal Asthma Control (SAC) and Absence of Controller Therapy (ACT)

  • Rate 1 (SAC): The percentage of patients aged 5-50 years as of the last day of the measurement year with persistent asthma who were dispensed more than 3 canisters of a short-acting beta2 agonist inhaler during the same 90-day period.

    Rate 2 (ACT): The percentage of patients aged 5-50 years as of the last day of the measurement year with persistent asthma who were dispensed more than 3 canisters of short-acting beta2 agonist inhalers over a 90-day period and who did not receive controller therapy during the same 90-day period.

    CBE ID
    0548